Understanding and Acting to Regulate Suicidal Behavior

Launched by UNIVERSITY HOSPITAL, MONTPELLIER · Nov 13, 2024

Keywords

ClinConnect Summary

The clinical trial titled "Understanding and Acting to Regulate Suicidal Behavior" is designed to help adolescents aged 12 to 16 who are experiencing thoughts of self-harm or suicidal behavior. Due to the increase in mental health issues among young people since the COVID-19 pandemic, this study will evaluate a program called CARES, which aims to help these adolescents manage their emotions and reduce harmful behaviors. The trial will compare two groups: one group will receive the CARES program alone, while the other group will participate in the CARES program alongside their parents, who will be involved in a separate training called Non-Violent Resistance (NVR).

To be eligible for this study, young participants must be between the ages of 12 and 16 years and have shown active thoughts or behaviors related to self-harm in the past six months. They will need to be referred by a healthcare professional, and certain conditions, like developmental disorders or language barriers, may exclude them from participating. Those who join the study can expect to engage in sessions that focus on understanding their feelings and learning healthier ways to cope. This trial is not yet recruiting participants, but it aims to provide valuable insights into how to better support adolescents struggling with these serious issues.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Age from 12 to 16 years 11 months old
• • Active suicidal ideation and/or suicidal behavior during the last 6 months
• • The patient is referred by a healthcare professional
• Exclusion Criteria:
• • Intellectual developmental disorder
• • Non-french speaking
• • Planned travel not allowing the complete following of the study
• • The patient, the parents or the legal guardian can not be correctly informed
• • The patient presents symptoms that prevent him from group interaction (behavior disorders, hallucinations, delirium)
• • The family already followed the same kind of program
• • The patient is already enrolled in a clinical trial or is taking a treatment off full market approval during 4 weeks before screening
• • The patient and the family are not affiliated to any healthcare insurance
• • No signed consent from parents or a legual guardian nor one of the parental authority holder
• • The patient did not consent